Acadia Healthcare Reports Fourth Quarter 2022 Results
Acadia Healthcare Company (ACHC) reported a robust fourth quarter for 2022 with revenue of $675.3 million, a 13.8% increase from the previous year. Net income reached $61.1 million or $0.67 per diluted share. The company opened new facilities and added 290 beds in 2022, with plans for 300 more beds in 2023. Acadia expects 2023 revenue between $2.82 to $2.88 billion and adjusted EBITDA between $635 to $675 million. A conference call discussing these results is scheduled for February 28, 2023.
- Revenue increased by 13.8% year-over-year to $675.3 million.
- Net income of $61.1 million, or $0.67 per diluted share.
- Same facility revenue grew by 9.4%, with a 5.2% increase in revenue per patient day.
- Opened new facilities and added 290 beds in 2022, with plans for 300 more in 2023.
- Financial guidance for 2023 estimates revenue of $2.82 to $2.88 billion.
- Adjusted EBITDA decreased to $150.9 million from $156.1 million year-over-year.
- Recorded a $5.9 million unfavorable adjustment to liability reserves.
Company Provides Full Year and First Quarter 2023 Guidance
Fourth Quarter Highlights
-
Revenue totaled
, an increase of$675.3 million 13.8% over the fourth quarter of 2021 -
Same facility revenue increased
9.4% compared to the fourth quarter of 2021, including an increase in revenue per patient day of5.2% and an increase in patient days of4.0% -
Net income attributable to Acadia totaled
, or$61.1 million per diluted share, and adjusted income from continuing operations attributable to Acadia stockholders totaled$0.67 , or$68.1 million per diluted share, which included$0.74 of income from the$0.04 Provider Relief Fund (“PRF”) established under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act -
Adjusted EBITDA totaled
, which included$150.9 million of income from the PRF established under the CARES Act$5.2 million -
Recorded a
unfavorable adjustment to professional and general liability reserves relating to the settlement or expected settlement of certain prior year claims relating primarily to the 2017 to 2018 period$5.9 million -
Opened a joint venture facility with Lutheran Health Network, in Ft.
Wayne, Indiana , and added seven new Comprehensive Treatment Centers (“CTCs”) through acquiring four existing facilities and opening three de novos
Fourth Quarter Results
The Company reported revenue of
During the fourth quarter of 2022, the Company recorded
The Company also recorded an unfavorable adjustment of
Net income attributable to Acadia stockholders for the fourth quarter of 2022 was
For the fourth quarter of 2022, Acadia’s same facility revenue increased
Strategic Investments for Long-Term Growth
“During the fourth quarter of 2022, we made further progress in meeting our growth objectives across each of our service lines. As demand for our services continues to grow, we have made the necessary investments in our operations to support sustained long-term growth. We believe our five distinct growth pathways will enable the Company to meet this demand and extend our market reach.
“Our first pathway, facility expansions, remains a primary driver of our growth, as this pathway allows us to efficiently expand services in established markets by utilizing our existing infrastructure and experienced staff. We added 80 beds to our existing facilities during the fourth quarter, finishing the year with a strong second half of 212 bed additions and bringing our total number to 290 for the year. Looking ahead, we expect to add approximately 300 beds through facility expansions in 2023.
“A second important growth pathway is to identify underserved markets for behavioral healthcare services and develop wholly owned de novo facilities that bridge this gap and help meet the critical community need. In
“We also continued to expand our network of CTCs, specifically designed to meet the growing and critical need for addiction treatment, especially for patients dealing with opioid use disorder. During the fourth quarter, we opened three new CTCs in
Hunter added, “Forming strategic partnerships is a third attractive growth pathway for Acadia. We have been fortunate to establish strong relationships with leading healthcare providers and premier healthcare systems across the country who want to expand behavioral healthcare treatment options in their respective communities. We bring the clinical expertise and experience they need to deliver high quality care, while we have an opportunity to leverage the providers’ market presence and established relationships in their communities. During the third quarter, we opened a new 90-bed facility with our joint venture partner,
“For our fourth pathway, we have a very disciplined focus on M&A opportunities and continue to look for selective acquisitions that complement our growth strategy and are incremental to our financial objectives. During the fourth quarter of 2022, we acquired four CTCs from
“For the fifth growth pathway, we remain focused on extending the continuum of care across our facilities and identifying additional ways to support patients. During the fourth quarter of 2022, we expanded our network of step-down programs by adding Intensive Outpatient Programs (IOP) across several of the communities that we serve. To further support our growth objectives, we also continued to implement our strategy of improving cross-referral opportunities between our facilities by launching the program to several strategically identified regions,” added Hunter.
Cash and Liquidity
Maintaining a strong financial position will continue to be a top priority for Acadia in 2023. As of
During the fourth quarter, the Company completed its repayment of amounts received pursuant to the Medicare Accelerated and Advanced Payment Program under the CARES Act. Of the
Looking Ahead
“We are proud of our results for 2022, and even more proud of our vitally important work to support expanding patient populations in order to make a positive difference in more communities. Acadia has created a strong foundation to build upon during a time of unprecedented demand for behavioral healthcare services. We also see a growing recognition among providers that behavioral health issues are integral to overall patient health. A 2022 study from
“As we look to the year ahead, we are focused on increasing our pace of growth and capitalizing on expansion opportunities across our service lines. At the same time, we will be enhancing the delivery of care we provide and strengthening our capabilities through our investments in people, processes and technology. Across our network of 250 facilities, we have a shared mission to provide high quality, differentiated behavioral healthcare services, and we look forward to the opportunities ahead for Acadia in 2023 and beyond,” concluded Hunter.
Financial Guidance
Acadia today narrowed its previously announced financial guidance for 2023, as follows:
|
2023 |
Revenue |
|
Adjusted EBITDA |
|
Adjusted earnings per diluted share |
|
Interest expense |
|
Tax rate |
|
Depreciation and amortization expense |
|
Stock compensation expense |
|
Operating cash flows |
|
Expansion capital expenditures |
|
Maintenance capital expenditures |
|
IT capital expenditures |
|
Acadia also established financial guidance for the first quarter of 2023, as follows:
First Quarter 2023 |
|
Revenue |
|
Adjusted EBITDA |
|
Adjusted earnings per diluted share |
|
The Company’s guidance does not include the impact of any future acquisitions, divestitures, transaction-related expenses or recognition of additional income from the CARES Act.
Conference Call
Acadia will hold a conference call to discuss its fourth quarter financial results at
About Acadia
Acadia is a leading provider of behavioral healthcare services across
Forward-Looking Information
This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) potential disruptions to our information technology systems or a cybersecurity incident; and (vii) potential operating difficulties, including, without limitation, disruption to the
Condensed Consolidated Statements of Operations | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended |
Year Ended |
|||||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
(In thousands, except per share amounts) | ||||||||||||||||
Revenue | $ |
675,295 |
|
$ |
593,480 |
|
$ |
2,610,399 |
|
$ |
2,314,394 |
|
||||
Salaries, wages and benefits (including equity-based compensation expense of |
|
365,702 |
|
|
321,120 |
|
|
1,393,434 |
|
|
1,243,804 |
|
||||
Professional fees |
|
40,295 |
|
|
34,824 |
|
|
158,013 |
|
|
136,739 |
|
||||
Supplies |
|
25,909 |
|
|
23,004 |
|
|
100,200 |
|
|
90,702 |
|
||||
Rents and leases |
|
11,682 |
|
|
9,829 |
|
|
45,462 |
|
|
38,519 |
|
||||
Other operating expenses |
|
93,922 |
|
|
79,076 |
|
|
349,277 |
|
|
301,339 |
|
||||
Income from provider relief fund |
|
(5,245 |
) |
|
(17,900 |
) |
|
(21,451 |
) |
|
(17,900 |
) |
||||
Depreciation and amortization |
|
30,142 |
|
|
28,368 |
|
|
117,769 |
|
|
106,717 |
|
||||
Interest expense, net |
|
19,405 |
|
|
15,573 |
|
|
69,760 |
|
|
76,993 |
|
||||
Debt extinguishment costs |
|
— |
|
|
— |
|
|
— |
|
|
24,650 |
|
||||
Loss on impairment |
|
— |
|
|
— |
|
|
— |
|
|
24,293 |
|
||||
Transaction-related expenses |
|
5,411 |
|
|
3,458 |
|
|
23,792 |
|
|
12,778 |
|
||||
Total expenses |
|
587,223 |
|
|
497,352 |
|
|
2,236,256 |
|
|
2,038,634 |
|
||||
Income from continuing operations before income taxes |
|
88,072 |
|
|
96,128 |
|
|
374,143 |
|
|
275,760 |
|
||||
Provision for income taxes |
|
24,927 |
|
|
24,609 |
|
|
94,110 |
|
|
67,557 |
|
||||
Income from continuing operations |
|
63,145 |
|
|
71,519 |
|
|
280,033 |
|
|
208,203 |
|
||||
Loss from discontinued operations, net of taxes |
|
— |
|
|
— |
|
|
— |
|
|
(12,641 |
) |
||||
Net income |
|
63,145 |
|
|
71,519 |
|
|
280,033 |
|
|
195,562 |
|
||||
Net income attributable to noncontrolling interests |
|
(2,021 |
) |
|
(1,241 |
) |
|
(6,894 |
) |
|
(4,927 |
) |
||||
Net income attributable to |
$ |
61,124 |
|
$ |
70,278 |
|
$ |
273,139 |
|
$ |
190,635 |
|
||||
Basic earnings per share attributable to stockholders: |
||||||||||||||||
Income from continuing operations attributable to |
$ |
0.68 |
|
$ |
0.79 |
|
$ |
3.05 |
|
$ |
2.29 |
|
||||
Loss from discontinued operations |
|
— |
|
|
— |
|
|
— |
|
$ |
(0.14 |
) |
||||
Net income attributable to |
$ |
0.68 |
|
$ |
0.79 |
|
$ |
3.05 |
|
$ |
2.15 |
|
||||
Diluted earnings per share attributable to stockholders: |
||||||||||||||||
Income from continuing operations attributable to |
$ |
0.67 |
|
$ |
0.77 |
|
$ |
2.98 |
|
$ |
2.24 |
|
||||
Loss from discontinued operations |
|
— |
|
|
— |
|
|
— |
|
$ |
(0.14 |
) |
||||
Net income attributable to |
$ |
0.67 |
|
$ |
0.77 |
|
$ |
2.98 |
|
$ |
2.10 |
|
||||
Weighted-average shares outstanding: | ||||||||||||||||
Basic |
|
89,897 |
|
|
89,020 |
|
|
89,680 |
|
|
88,769 |
|
||||
Diluted |
|
91,872 |
|
|
91,038 |
|
|
91,555 |
|
|
90,793 |
|
Condensed Consolidated Balance Sheets | |||||||
(Unaudited) | |||||||
2022 |
2021 |
||||||
(In thousands) | |||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ |
97,649 |
$ |
133,813 |
|
||
Accounts receivable, net |
|
322,439 |
|
281,332 |
|
||
Other current assets |
|
86,037 |
|
79,886 |
|
||
Total current assets |
|
506,125 |
|
495,031 |
|
||
Property and equipment, net |
|
1,952,045 |
|
1,771,159 |
|
||
|
2,222,805 |
|
2,199,937 |
|
|||
Intangible assets, net |
|
76,041 |
|
70,145 |
|
||
Deferred tax assets |
|
2,950 |
|
3,080 |
|
||
Operating lease right-of-use assets |
|
135,238 |
|
133,761 |
|
||
Other assets |
|
92,697 |
|
94,965 |
|
||
Total assets | $ |
4,987,901 |
$ |
4,768,078 |
|
||
LIABILITIES AND EQUITY | |||||||
Current liabilities: | |||||||
Current portion of long-term debt | $ |
21,250 |
$ |
18,594 |
|
||
Accounts payable |
|
104,723 |
|
98,575 |
|
||
Accrued salaries and benefits |
|
125,298 |
|
137,845 |
|
||
Current portion of operating lease liabilities |
|
26,463 |
|
23,348 |
|
||
Other accrued liabilities |
|
110,592 |
|
126,499 |
|
||
Total current liabilities |
|
388,326 |
|
404,861 |
|
||
Long-term debt |
|
1,364,541 |
|
1,478,626 |
|
||
Deferred tax liabilities |
|
92,588 |
|
74,368 |
|
||
Operating lease liabilities |
|
116,429 |
|
116,841 |
|
||
Other liabilities |
|
125,033 |
|
110,505 |
|
||
Total liabilities |
|
2,086,917 |
|
2,185,201 |
|
||
Redeemable noncontrolling interests |
|
88,257 |
|
65,388 |
|
||
Equity: | |||||||
Common stock |
|
899 |
|
890 |
|
||
Additional paid-in capital |
|
2,658,440 |
|
2,636,350 |
|
||
Retained earnings (accumulated deficit) |
|
153,388 |
|
(119,751 |
) |
||
Total equity |
|
2,812,727 |
|
2,517,489 |
|
||
Total liabilities and equity | $ |
4,987,901 |
$ |
4,768,078 |
|
||
Condensed Consolidated Statements of Cash Flows | ||||||||
(Unaudited) | ||||||||
Year Ended |
||||||||
2022 |
2021 |
|||||||
(In thousands) | ||||||||
Operating activities: | ||||||||
Net income | $ |
280,033 |
|
$ |
195,562 |
|
||
Adjustments to reconcile net income to net cash provided by continuing operating activities: | ||||||||
Depreciation and amortization |
|
117,769 |
|
|
106,717 |
|
||
Amortization of debt issuance costs |
|
3,261 |
|
|
4,071 |
|
||
Equity-based compensation expense |
|
29,635 |
|
|
37,530 |
|
||
Deferred income taxes |
|
16,545 |
|
|
11,772 |
|
||
Loss from discontinued operations, net of taxes |
|
— |
|
|
12,641 |
|
||
Debt extinguishment costs |
|
— |
|
|
24,650 |
|
||
Loss on impairment |
|
— |
|
|
24,293 |
|
||
Other |
|
2,680 |
|
|
491 |
|
||
Change in operating assets and liabilities, net of effect of acquisitions: | ||||||||
Accounts receivable, net |
|
(41,978 |
) |
|
2,448 |
|
||
Other current assets |
|
(17,626 |
) |
|
1,968 |
|
||
Other assets |
|
2,252 |
|
|
(10,770 |
) |
||
Accounts payable and other accrued liabilities |
|
5,174 |
|
|
6,164 |
|
||
Accrued salaries and benefits |
|
6,804 |
|
|
9,755 |
|
||
Other liabilities |
|
15,090 |
|
|
(14,940 |
) |
||
Government relief funds |
|
(39,070 |
) |
|
(38,128 |
) |
||
Net cash provided by continuing operating activities |
|
380,569 |
|
|
374,224 |
|
||
Net cash provided by discontinued operating activities |
|
— |
|
|
253 |
|
||
Net cash provided by operating activities |
|
380,569 |
|
|
374,477 |
|
||
Investing activities: | ||||||||
Cash paid for acquisitions, net of cash acquired |
|
(9,507 |
) |
|
(139,015 |
) |
||
Cash paid for capital expenditures |
|
(296,149 |
) |
|
(244,811 |
) |
||
Proceeds from U. |
|
— |
|
|
1,511,020 |
|
||
Settlement of foreign currency derivatives |
|
— |
|
|
(84,795 |
) |
||
Proceeds from sale of property and equipment |
|
7,074 |
|
|
3,493 |
|
||
Cash paid for purchase of finance lease |
|
— |
|
|
(31,401 |
) |
||
Other |
|
(7,248 |
) |
|
(1,394 |
) |
||
Net cash (used in) provided by investing activities |
|
(305,830 |
) |
|
1,013,097 |
|
||
Financing activities: | ||||||||
Borrowings on long-term debt |
|
— |
|
|
425,000 |
|
||
Borrowings on revolving credit facility |
|
— |
|
|
500,000 |
|
||
Principal payments on revolving credit facility |
|
(95,000 |
) |
|
(330,000 |
) |
||
Principal payments on long-term debt |
|
(18,594 |
) |
|
(7,969 |
) |
||
Repayment of long-term debt |
|
— |
|
|
(2,227,935 |
) |
||
Payment of debt issuance costs |
|
— |
|
|
(7,964 |
) |
||
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises |
|
(6,179 |
) |
|
16,295 |
|
||
Contributions from noncontrolling partners in joint ventures |
|
15,362 |
|
|
4,536 |
|
||
Distributions to noncontrolling partners in joint ventures |
|
(1,004 |
) |
|
(1,588 |
) |
||
Acquisition of ownership interests from noncontrolling partners |
|
(5,540 |
) |
|
— |
|
||
Other |
|
52 |
|
|
(6,900 |
) |
||
Net cash used in financing activities |
|
(110,903 |
) |
|
(1,636,525 |
) |
||
Effect of exchange rate changes on cash |
|
— |
|
|
4,067 |
|
||
Net decrease in cash and cash equivalents |
|
(36,164 |
) |
|
(244,884 |
) |
||
Cash and cash equivalents at beginning of the period |
|
133,813 |
|
|
378,697 |
|
||
Cash and cash equivalents at end of the period | $ |
97,649 |
|
$ |
133,813 |
|
||
Effect of acquisitions: | ||||||||
Assets acquired, excluding cash | $ |
10,756 |
|
$ |
176,365 |
|
||
Liabilities assumed |
|
(1,249 |
) |
|
(37,350 |
) |
||
Cash paid for acquisitions, net of cash acquired | $ |
9,507 |
|
$ |
139,015 |
|
||
Operating Statistics | |||||||||||||||
(Unaudited, Revenue in thousands) | |||||||||||||||
Three Months Ended |
Year Ended |
||||||||||||||
|
2022 |
|
2021 |
|
% Change |
|
2022 |
|
2021 |
|
% Change |
||||
Revenue | $ |
645,085 |
$ |
589,488 |
|
$ |
2,504,285 |
$ |
2,293,394 |
|
|||||
|
708,485 |
|
681,061 |
|
|
2,818,614 |
|
2,749,903 |
|
||||||
Admissions |
|
43,777 |
|
42,663 |
|
|
176,981 |
|
178,846 |
- |
|||||
Average Length of Stay (2) |
|
16.2 |
|
16.0 |
|
|
15.9 |
|
15.4 |
|
|||||
Revenue per |
$ |
911 |
$ |
866 |
|
$ |
888 |
$ |
834 |
|
|||||
Adjusted EBITDA margin (3) |
|
|
|
|
-270 bps |
|
|
|
|
70 bps |
|||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
|
|
|
-60 bps |
|
|
|
|
60 bps |
|||||
Revenue | $ |
675,295 |
$ |
593,480 |
|
$ |
2,610,399 |
$ |
2,314,394 |
|
|||||
|
736,695 |
|
686,584 |
|
|
2,916,500 |
|
2,775,061 |
|
||||||
Admissions |
|
46,375 |
|
42,691 |
|
|
186,305 |
|
179,075 |
|
|||||
Average Length of Stay (2) |
|
15.9 |
|
16.1 |
- |
|
15.7 |
|
15.5 |
|
|||||
Revenue per |
$ |
917 |
$ |
864 |
|
$ |
895 |
$ |
834 |
|
|||||
Adjusted EBITDA margin (3) |
|
|
|
|
-370 bps |
|
|
|
|
-50 bps |
|||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
|
|
|
-150 bps |
|
|
|
|
-50 bps |
|||||
(1) Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services. | |||||||||||||||
(2) Average length of stay is defined as patient days divided by admissions. | |||||||||||||||
(3) For the three months ended |
Reconciliation of Net Income Attributable to |
||||||||||||
(Unaudited) | ||||||||||||
Three Months Ended |
Year Ended |
|||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||
(in thousands) | ||||||||||||
Net income attributable to |
$ |
61,124 |
$ |
70,278 |
$ |
273,139 |
$ |
190,635 |
||||
Net income attributable to noncontrolling interests |
|
2,021 |
|
1,241 |
|
6,894 |
|
4,927 |
||||
Loss from discontinued operations, net of taxes |
|
— |
|
— |
|
— |
|
12,641 |
||||
Provision for income taxes |
|
24,927 |
|
24,609 |
|
94,110 |
|
67,557 |
||||
Interest expense, net |
|
19,405 |
|
15,573 |
|
69,760 |
|
76,993 |
||||
Depreciation and amortization |
|
30,142 |
|
28,368 |
|
117,769 |
|
106,717 |
||||
EBITDA |
|
137,619 |
|
140,069 |
|
561,672 |
|
459,470 |
||||
Adjustments: | ||||||||||||
Equity-based compensation expense (a) |
|
7,890 |
|
12,542 |
|
29,635 |
|
37,530 |
||||
Transaction-related expenses (b) |
|
5,411 |
|
3,458 |
|
23,792 |
|
12,778 |
||||
Debt extinguishment costs (c) |
|
— |
|
— |
|
— |
|
24,650 |
||||
Loss on impairment (d) |
|
— |
|
— |
|
— |
|
24,293 |
||||
Adjusted EBITDA | $ |
150,920 |
$ |
156,069 |
$ |
615,099 |
$ |
558,721 |
||||
Adjusted EBITDA margin |
|
|
|
|
|
|
|
|
||||
Adjusted EBITDA excluding income from provider relief fund | $ |
145,675 |
$ |
138,169 |
$ |
593,648 |
$ |
540,821 |
||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
|
|
|
|
|
|
|
||||
See footnotes on page 12. |
Reconciliation of Net Income Attributable to |
||||||||||||||||
Adjusted Income Attributable to |
||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended |
Year Ended |
|||||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
(in thousands, except per share amounts) | ||||||||||||||||
Net income attributable to |
$ |
61,124 |
|
$ |
70,278 |
|
$ |
273,139 |
|
$ |
190,635 |
|
||||
Loss from discontinued operations, net of taxes |
|
— |
|
|
— |
|
|
— |
|
|
12,641 |
|
||||
Adjustments to income: | ||||||||||||||||
Transaction-related expenses (b) |
|
5,411 |
|
|
3,458 |
|
|
23,792 |
|
|
12,778 |
|
||||
Debt extinguishment costs (c) |
|
— |
|
|
— |
|
|
— |
|
|
24,650 |
|
||||
Loss on impairment (d) |
|
— |
|
|
— |
|
|
— |
|
|
24,293 |
|
||||
Provision for income taxes |
|
24,927 |
|
|
24,609 |
|
|
94,110 |
|
|
67,557 |
|
||||
Adjusted income from continuing operations before income taxes attributable to |
|
91,462 |
|
|
98,345 |
|
|
391,041 |
|
|
332,554 |
|
||||
Income tax effect of adjustments to income (e) |
|
23,405 |
|
|
24,791 |
|
|
100,067 |
|
|
87,500 |
|
||||
Adjusted income from continuing operations attributable to |
|
68,057 |
|
|
73,554 |
|
|
290,974 |
|
|
245,054 |
|
||||
Income from provider relief fund, net of taxes |
|
(3,822 |
) |
|
(13,044 |
) |
|
(15,631 |
) |
|
(13,044 |
) |
||||
Adjusted income from continuing operations attributable to from provider relief fund |
$ |
64,235 |
|
$ |
60,510 |
|
$ |
275,343 |
|
$ |
232,010 |
|
||||
Weighted-average shares outstanding - diluted |
|
91,872 |
|
|
91,038 |
|
|
91,555 |
|
|
90,793 |
|
||||
Adjusted income from continuing operations attributable to |
$ |
0.74 |
|
$ |
0.81 |
|
$ |
3.18 |
|
$ |
2.70 |
|
||||
Income from provider relief fund, net of taxes, per diluted share |
|
(0.04 |
) |
|
(0.14 |
) |
|
(0.17 |
) |
|
(0.14 |
) |
||||
Adjusted income from continuing operations attributable to from provider relief fund, per diluted share |
$ |
0.70 |
|
$ |
0.67 |
|
$ |
3.01 |
|
$ |
2.56 |
|
||||
See footnotes on page 12. |
Footnotes | |
We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the |
|
• EBITDA: net income attributable to |
|
• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction-related expenses, debt extinguishment costs and loss on impairment. | |
• Adjusted EBITDA excluding income from provider relief fund: Adjusted EBITDA adjusted for income from provider relief fund. | |
• Adjusted EBITDA margin: Adjusted EBITDA divided by revenue. | |
• Adjusted EBITDA margin excluding income from provider relief fund: Adjusted EBITDA excluding income from provider relief fund divided by revenue. | |
• Adjusted income from continuing operations before income taxes attributable to |
|
• Adjusted income from continuing operations attributable to |
|
• Adjusted income from continuing operations attributable to |
|
• Adjusted income attributable to |
|
• Adjusted income attributable to |
|
The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in |
|
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided and whether including or excluding income from provider relief fund, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. | |
(a) Represents the equity-based compensation expense of Acadia. | |
(b) Represents transaction-related expenses incurred by Acadia primarily related to termination, restructuring, management transition, acquisition and other similar costs. | |
(c) Represents debt extinguishment costs recorded during the first quarter of 2021 in connection with the redemption of the |
|
(d) The Company opened a 260-bed replacement hospital in |
|
(e) Represents the income tax effect of adjustments to income based on tax rates of |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005791/en/
Vice President, Investor Relations
(615) 861-6000
Source:
FAQ
What were Acadia's fourth quarter 2022 earnings results?
What is Acadia's guidance for 2023?
How many new facilities did Acadia open in 2022?
What was Acadia's adjusted EBITDA for the fourth quarter of 2022?